Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by mol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Hofman, Véronique, Lassalle, Sandra, Bence, Coraline, Long-Mira, Elodie, Nahon-Estève, Sacha, Heeke, Simon, Lespinet-Fabre, Virginie, Butori, Catherine, Ilié, Marius, Hofman, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2018
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5876645/
https://ncbi.nlm.nih.gov/pubmed/29534030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10030070
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados